Nirsevimab: Alleviating the Burden Of RSV Morbidity in Young Children
- Marcus Wing Choy Loe; Helen Soenong; Evelyn Lee; Jean Li-Kim-Moy; Phoebe Williams; Kee Thai Yeo
PMID: 39150043DOI: https://dx.doi.org/10.1111/jpc.16643
Access Resources
About
This article reviews the real-world data that supports the effectiveness of nirsevimab, a monoclonal antibody that helps protect young children from RSV. Studies have demonstrated significant reductions in RSV-related hospitalizations with nirsevimab treatment. Strategies focus on seasonal administration for infants. While nirsevimab offers public health benefits, economic factors and logistics must be considered for its adoption. While promising, it needs careful planning for widespread use in different countries due to costs and logistics.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.